Clinical Trial

A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main goals of this study are to evaluate the safety and efficacy of casdozokitug in combination with toripalimab plus bevacizumab and to define a recommended dose for casdozokitug in combination with toripalimab plus bevacizumab.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-04-14
Trial Details
NCT Number NCT06679985
Lead Sponsor Coherus Oncology, Inc.
Conditions Hepatocellular Carcinoma
Enrollment 72 participants
Start Date 2024-12-20
Primary Completion 2027-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-15